Novo, WuXi AppTec and Alexandria Venture Investments all invested in a Lepu Medical-led round that will support clinical trials for two cancer drug candidates.

Glympse Bio, a medical diagnostic sensor spinout from MIT, has secured $22m in a series A round backed by Gilead Sciences and Heritage Provider Network.

Canada’s Strategic Innovation Fund will provide $19.2m for accelerator Creative Destruction Lab over four years with the aim of supporting more than 1,300 science-focused companies.

The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.

SR One co-led a round that included Celgene and Alexandria Venture Investments, as Gotham Therapeutics came out of stealth.

Ascension Ventures was among the existing investors in a round in which Horizon Technology Finance put up $6m of equity financing and $15m of debt.

Cornell spinout Gotham Therapeutics has come out of stealth with a series A round co-led by SR One, Versant Ventures and Forbion.

Glympse Bio, a medical diagnostic sensor spinout from MIT, has secured $22m in a series A round ahead of clinical trials targeting fatty liver disease and cancer.

The university’s Office of Technology Transfer launched 21 spinouts while achieving a 10% rise in inventions disclosed and a record number of licences and options agreed.

Johns Hopkins oncology diagnostics spinout PGDx had previously raised approximately $99m.